Leukemic tumor cell

Leukemic tumor cells are malignant hematopoietic cells that arise from the clonal expansion of hematopoietic stem or progenitor cells in the bone marrow (StatPearls, 2023). These cells are characterized by a failure to undergo normal maturation and an evasion of programmed cell death, leading to the displacement of healthy blood-forming elements (NCI, 2024). While the term describes the disease-causing entity, it does not refer to a specific molecular target; instead, these cells express various receptors and enzymes that serve as targets for therapy (NIH, 2023). For instance, targeted agents like imatinib inhibit the BCR-ABL protein within these cells, while monoclonal antibodies like rituximab target surface antigens (PubMed, 2022). The elimination of these cells is the primary goal of leukemia treatment, often monitored through biomarkers like specific genetic mutations or cell surface clusters of differentiation (Nature Reviews Cancer, 2021). Understanding the heterogeneity of these cells is vital for overcoming therapeutic resistance and preventing disease relapse (Journal of Clinical Oncology, 2023). Therapeutic strategies often involve a combination of cytotoxic chemotherapy and precision medicine to eradicate the leukemic clone (American Cancer Society, 2024).

Other names

Leukemia cellLeukemic blastMalignant hematopoietic cellLeukocyte cancer cell

Drugs targeting leukemic cells typically act by inhibiting specific oncogenic drivers, inducing programmed cell death, or utilizing immune-mediated clearance via surface antigen recognition.